1Libby P. Inflammation in atheroselerosis[J]. Nature,2002 ;420:868-74.
2Hersh EV, Lally ET, Moore PA. Update on cyclooxygenase inhibitors : has a third COX isoform entered the fray [J]? Curr Med Res Opin,2005 ;21.
3Stemme V, Swedenborg J, Claesson H, et al. Expression of cyclooxygenase-2 in human atherosclerotic carotid arteries[J]. Eur J Vasc Endovasc Sug,2000;20(2) :146-52.
4Sehonbeek U, Sukhova GK, Greber P,et al. Augmented expression of eyclooxygenase-2 in human atherosclerotic lesions [J]. Am J Pathol, 1999; 155(4) :1281-91.
5Me Geer PL,Mc Geer EG,Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques [J]. Exp Gerontol,2002 ;37 (7) :925- 9.
6Linton MF, Fasio S. Cyclooxygenase-2 and atherosclerosis [J]. Curr Opin Lipidol, 2002 ; 13 ( 5 ) :497-504.
7Burleigh ME, Bahaev VR, Ooates JA, et al. Cyclooxygenase-2 promotes early atheroselerotic lesion formation in LDL receptor deficient mice [J]. Circulation ,2002 ; 105 ( 15 ) : 1816-23.
8Beloqui O, Paramo JA, Orbe J, et al. Monocyte cycloxygenase-2 overaclivity:a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors [J] Eur Heart J,2005 ;26 (2) :153-8.
9Paramo JA, Rodrlguez JA, Beloqui O, et al. Monocyte eyclooxygenase-2 activity:a new therapeutic target for atheroselerosis [J]? Curr Drug Targets Cardiovasc Haematol Disord,2005 ;5 (4) : 303-11.
10Cipollone F. COX-2 and prostaglandins in atherosclerosis [J]. Lupus, 2005;14 (9) :756-9.
二级参考文献20
1Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis.Circulation,2002,105(9):1135-1143.
2Schieffer B,Drexler H.Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors,angiotensin-converting enzyme inhibitors,cyclooxygenase-2 inhibitors,and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.Am J Cardiol,2003,91(12A):12H-18H.
3Paigen B,Morrow A,Holmes P,et al.Quantitative assessment of atherosclerotic lesions in mice.Atherosclerosis,1987,68:231-240.
5Hernandez-Presa M,Martin-Ventura JL,Ortego M,et al.Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.Atherosclerosis,2002,160:49-58.
6Wu D,Hayek MG,Meydani SN.Vitamin E and macrophage cyclooxygenase regulation in the aged.J Nutr,2001,131:382S-388S.
7Nakashima Y,Plump AS,Raines EW,et al.Apo E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.Arteriosclerosis and Thrombosis,1994,14(1):133-140.
9Burleigh ME,Babaev VR,Oates JA,et al.Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.Circulation,2002,105:1816-1823.
10Belton OA,Duffy A,Toomey S,et al.Cyclooxygenase isoforms and platelet vessel wall interactions in the Apolipoprotein E knockout mouse model of atherosclerosis.Circulation,2003,108:3017-3023.
5Yokota C,Kaji T,Kuge Y,et al. Temporal and topographic profiles of cyelooxygenase 2 expression during 24h of focal brain ishemia in rats[J].Neurosci Lett, 2004,357 : 219-222.
6Wang Y, Dang XL, Xiao XH, et al. A non-steroidal anti-inflam matory agent provides significant protection during focal ische mic stroke with decreased expression of matrix metalloprotein ases[J]. Curr Neurovase Res, 2007,4(3) :176-188.
7Candelario-Jalil E. Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences[J]. Pharmacol Res,2008,57(4) :266-273.
8McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase:a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2[J].JAMA,2006,296(13):1 633-1 644.
9Chencvard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease[J]. Circulation, 2003, 107(3):405-409.
10Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis [ J ]. J Atheroscler Thromb,2011,18 (5) :351-358.
